Access DB# 136892

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Alton Ryan Examiner #: 74458 Date: 11/2/04
Art Unit: 1616 Phone Number 30-2-0621 Serial Number: 10/049821
Mail Box and Bldg/Room Location: REM 4A39 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

_____

Earliest Priority Filing Date: _____

***For Sequence Searches Only** Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Search: #
(1) Structure of claim 4
(2) inflammatory or analgesic
(3) Combine (1) + (2)

****

STAFF USE ONLY	**Type of Search**		**Vendors and cost where applicable**
Searcher: Skorgan	NA Sequence (#)		STN
Searcher Phone #:	AA Sequence (#)		Dialog
Searcher Location:	Structure (#)		Questel/Orbit
Date Searcher Picked Up:	Bibliographic		Dr.Link
Date Completed: 11/2/04	Litigation		Lexis/Nexis
Searcher Prep & Review Time:	Fulltext		Sequence Systems
Clerical Prep Time:	Patent Family		WWW/Internet
Online Time:	Other		Other (specify)

PTO-1590 (8-01)

STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 136892

TO: Alton Pryor
Location: Rem 4A39
Art Unit: 1616
November 2, 2004

Case Serial Number: 10/049821

From: P. Sheppard
Location: Remsen Building
Phone: (571) 272-2529

sheppard@uspto.gov

Search Notes

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 14:12:28 ON 02 NOV 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 2 Nov 2004  VOL 141 ISS 19
FILE LAST UPDATED: 1 Nov 2004  (20041101/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=>
=>

=> d stat que
L3               STR
```




```
VAR G1=C/N
VAR G2=C/N/O/S
REP G3=(1-4) C
REP G5=(2-4) A
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  15

STEREO ATTRIBUTES: NONE
L4            92 SEA FILE=REGISTRY SSS FUL L3
L6               SEL  PLU=ON  L4 1- CHEM :      96 TERMS
L7            38 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L6
L8        165853 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("ANTI-INFLAMMATORY AGENTS"/CV
                  OR "INFLAMMATION INHIBITORS"/CV OR "INFLAMMATION INHIBITORS
                 AND ANTIARTHRITICS"/CV OR "ANTI-INFLAMMATORY DRUGS"/CV OR
                 "ANTI-INFLAMMATORY SUBSTANCES"/CV OR ANTIINFLAMMATANTS/CV OR
```

ANTIINFLAMMATORIES/CV OR ANTIPHLOGISTICS/CV OR ANTIARTHRITICS/C
V OR "ANTIRHEUMATIC AGENTS"/CV OR MELITTIN/CV OR "INFLAMMATION
INHIBITORS (L) ANTIARTHRITICS"/CV OR "INFLAMMATION INHIBITORS
(L) ANTIRHEUMATICS"/CV OR "INFLAMMATION INHIBITORS (L)
NONSTEROIDAL"/CV OR "INFLAMMATION INHIBITORS (L) TOPICAL"/CV
OR ANTIASTHMATICS/CV OR CORTICOSTEROIDS/CV OR INFECTION/CV OR
INFLAMMATION/CV OR 1-TERT-BUTOXYCARBONYL-4-PIPERIDONE/CV OR
"6-METHOXY-2-NAPHTHYLACETIC ACID"/CV OR "BECLOMETHASONE
DIPROPIONATE"/CV OR CELECOXIB/CV OR CROMOLYN/CV OR DICLOFENAC/C
V OR "DICLOFENAC SODIUM"/CV OR DIFLUNISAL/CV OR ETANERCEPT/CV
OR "ETHYL 2-CHLOROACETOACETATE"/CV OR "ETHYL ISONIPECOTATE"/CV
OR ETODOLAC/CV OR FENBUFEN/CV OR FENOPROFEN/CV OR KETOROLAC/CV
OR "MECLOFENAMIC ACID"/CV OR "MEFENAMIC ACID"/CV OR MELOXICAM/C
V OR "METHYLPREDNISOLONE SODIUM SUCCINATE"/CV OR "NS 398"/CV
OR NABUMETONE/CV OR "NIFLUMIC ACID"/CV OR ROFECOXIB/CV OR
SUPROFEN/CV OR TENOXICAM/CV OR TOLMETIN/CV OR TRIAMCINOLONE/CV
OR "TRIAMCINOLONE ACETONIDE"/CV OR VALDECOXIB/CV OR VIDARABINE/
CV)

L9 134932 SEA FILE=HCAPLUS ABB=ON PLU=ON ("NERVOUS SYSTEM AGENTS"/CV
OR "NERVOUS SYSTEM DEPRESSANTS"/CV OR ANALGESICS/CV OR
ANODYNES/CV OR "ANTINOCICEPTIVE AGENTS"/CV OR "ANTINOCICEPTIVE
COMPOUNDS"/CV OR ANTINOCICEPTIVES/CV OR NARCOTICS/CV OR
OPIATES/CV OR "OPIATES AND OPIOIDS"/CV OR OPIOIDS/CV OR
BUTORPHANOL/CV OR ENKEPHALINS/CV OR "(D-PEN2, D-PEN5)ENKEPHALIN
"/CV OR DADLE/CV OR "LEUCINE ENKEPHALIN"/CV OR "METHIONINE
ENKEPHALIN"/CV OR PROENKEPHALIN/CV OR LOPERAMIDE/CV OR
NALBUPHINE/CV OR "OPIUM ALKALOIDS"/CV OR ANALGESIA/CV OR
ANESTHETICS/CV OR ANTIPYRETICS/CV OR "HYPNOTICS AND SEDATIVES"/
CV OR PAIN/CV OR "PAIN RECEPTORS"/CV OR VANILLOIDS/CV OR
ALFENTANIL/CV OR BUPIVACAINE/CV OR BUPRENORPHINE/CV OR
CODEINE/CV OR DEXTROMETHORPHAN/CV OR DICLOFENAC/CV OR DIFLUNISA
L/CV OR DIHYDROCODEINE/CV OR DIHYDROMORPHINE/CV OR FENTANYL/CV
OR GABAPENTIN/CV OR HYDROCODONE/CV OR HYDROMORPHONE/CV OR
KETOROLAC/CV OR MEPERIDINE/CV OR METAMIZOLE/CV OR MORPHINE/CV
OR "MORPHINE SULFATE"/CV OR NEOSTIGMINE/CV OR OXYCODONE/CV OR
REMIFENTANIL/CV OR ROPIVACAINE/CV OR SUFENTANIL/CV OR TRAMADOL/
CV)

L10 6 SEA FILE=HCAPLUS ABB=ON PLU=ON L7 AND (L8 OR L9)

=> d ibib abs kwic hitstr l10 1-6

L10 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:610036 HCAPLUS
DOCUMENT NUMBER: 141:145717
TITLE: Sedative non-benzodiazepine formulations
INVENTOR(S): O'Toole, Edel; Fogarty, Siobhan
PATENT ASSIGNEE(S): Biovail Laboratories Inc., Barbados
SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062564	A2	20040729	WO 2004-IB18	20040108
WO 2004062564	A3	20040910		

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AU, AZ, AZ, BA, BB,
BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR,
CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG,
ES, ES, FI, FI, GB, GD, GE, GE, GH, GH, GH, GM, HR, HR, HU, HU,

ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ

US 2003165566 A1 20030904 US 2003-338876 20030109
PRIORITY APPLN. INFO.: US 2003-338876 A 20030109
US 2002-346613P P 20020110

AB The invention provides for an enhanced absorption pharmaceutical composition comprising a plurality of microparticles, each microparticle comprising at least one sedative non-benzodiazepine, at least one spheronization aid and at least one solubility enhancer. The microparticles of the invention are further incorporated into an oral fast-dispersing dosage form.

IT Human
Hypnotics and Sedatives
Insomnia
Particle size distribution
Solubilizers
Spheronization
(sedative non-benzodiazepine formulations)

IT 50-70-4, Sorbitol, biological studies 60-87-7, Promethazine 87-99-0, Xylitol 113-18-8, Ethchlorvynol 151-21-3, Sodium lauryl sulfate, biological studies 302-17-0, Chloral hydrate 533-45-9, Clomethiazole 2218-68-0, Chloral betaine 9003-39-8, Polyvinylpyrrolidone 9005-65-6, Tween 80 18641-57-1, Glyceryl behenate 19794-93-5, Trazodone 25322-68-3D, ethers 43200-80-2, Zopiclone 82626-48-0, Zolpidem 83366-66-9, Nefazodone 85650-52-8, Mirtazapine 121548-04-7, Gelucire 44/14 121548-05-8, Gelucire 50/13 138729-47-2, Esopiclone 151319-34-5, Zaleplon 162883-07-0, Ccd-3693 **196597-26-9**, **TAK-375** 325715-02-4, Indiplon 565462-01-3, Co-32693 565462-02-4, Ip-100-9 565462-03-5, Pprt-211 727733-43-9, SC 72393
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(sedative non-benzodiazepine formulations)

IT **196597-26-9, TAK-375**
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(sedative non-benzodiazepine formulations)

RN 196597-26-9 HCAPLUS
CN Propanamide, N-[2-[(8S)-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:197432 HCAPLUS
DOCUMENT NUMBER: 140:296697
TITLE: **TAK-375**: treatment of insomnia
treatment of circadian rhythm disorders melatonin MT1/MT2 agonist

AUTHOR(S): Chilman-Blair, K.; Castaner, J.; Silvestre, J. S.; Bayes, M.
CORPORATE SOURCE: Prous Science, Barcelona, 08080, Spain
SOURCE: Drugs of the Future (2003), 28(10), 950-958
CODEN: DRFUD4; ISSN: 0377-8282
PUBLISHER: Prous Science
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Melatonin is a neurohormone produced in the pineal gland that is involved in the regulation of circadian rhythm function. It works through activation of its intrinsic receptors found in the suprachiasmatic nucleus (SCN) within the hypothalamus. Melatonin synthesis is under direct neural control from SCN firing. The sleep/wake cycle is a circadian rhythm controlled by this neural complex. Problems in the functioning of this system can therefore lead to sleep disorders. While melatonin itself has been shown to be effective in the treatment of sleep disorders, problems due to its ubiquitous action in the brain have limited its use for this indication. **TAK-375** is a potent melatonin receptor agonist, specific for the ML1 receptor subtype known to be intricately involved in circadian rhythm function. **TAK-375** has been heralded as an exciting new drug candidate for the treatment of patients with insomnia and circadian rhythm dysfunction. Phase III trials are currently under way to test the drug's viability for use in patients with sleep disorders.

TI **TAK-375**: treatment of insomnia. . .

AB . . . for this indication. **TAK-375** is a potent. . . circadian rhythm function. **TAK-375** has been heralded. . .

IT Sleep
(-waking cycle; melatonin MT1/MT2 agonist **TAK-375** treatment of patients with insomnia and circadian rhythm disorders)

IT Rhythm, biological
(circadian, regulation of; melatonin MT1/MT2 agonist **TAK-375** treatment of patients with insomnia and circadian rhythm disorders)

IT Sleep
(disorder; melatonin MT1/MT2 agonist **TAK-375** treatment of patients with insomnia and circadian rhythm disorders)

IT Aging, animal
(elderly; melatonin MT1/MT2 agonist **TAK-375** treatment of patients with insomnia and circadian rhythm disorders)

IT Brain
(hypothalamus, suprachiasmatic nucleus; melatonin MT1/MT2 agonist **TAK-375** treatment of patients with insomnia and circadian rhythm disorders)

IT Human
Hypnotics and Sedatives
Insomnia
Pineal gland
(melatonin MT1/MT2 agonist **TAK-375** treatment of patients with insomnia and circadian rhythm disorders)

IT Neurohormones
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(melatonin MT1/MT2 agonist **TAK-375** treatment of patients with insomnia and circadian rhythm disorders)

IT Melatonin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type MT1, agonist; melatonin MT1/MT2 agonist **TAK-375** treatment of patients with insomnia and circadian rhythm disorders)

IT Melatonin receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type MT2, agonist; melatonin MT1/MT2 agonist **TAK-375** treatment of patients with insomnia and circadian rhythm disorders)

IT **196597-26-9P, TAK-375**
RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(melatonin MT1/MT2 agonist **TAK-375** treatment of patients with insomnia and circadian rhythm disorders)
IT 73-31-4, Melatonin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(melatonin MT1/MT2 agonist **TAK-375** treatment of patients with insomnia and circadian rhythm disorders)
IT **196597-26-9P, TAK-375**
RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(melatonin MT1/MT2 agonist **TAK-375** treatment of patients with insomnia and circadian rhythm disorders)
RN 196597-26-9 HCAPLUS
CN Propanamide, N-[2-[(8S)-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:897579 HCAPLUS
DOCUMENT NUMBER: 140:296592
TITLE: Recent progress of hypnotic drug therapy
AUTHOR(S): Nakajima, Toru; Sugano, Michi
CORPORATE SOURCE: School of Medicine, Kyorin University, Japan
SOURCE: Gendai Iryo (2003), 35(10), 2439-2446
CODEN: GEIRDK; ISSN: 0533-7259
PUBLISHER: Gendai Iryosha
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Japanese
AB A review. The history and characteristic of hypnotic drugs including ω1 selectivity, the influence of hypnotic drugs on the different sleeping stages, the metabolism of hypnotic drugs, and recent development of hypnotic drugs such as **TAK-375** etc. is reviewed.
AB . . . drugs such as **TAK-375** etc. is reviewed.
IT **Hypnotics and Sedatives**
(recent progress of hypnotic drug therapy)
IT **196597-26-9, TAK-375**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(recent progress of hypnotic drug therapy)
IT **196597-26-9, TAK-375**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(recent progress of hypnotic drug therapy)
RN 196597-26-9 HCAPLUS
CN Propanamide, N-[2-[(8S)-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L10 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:570816 HCAPLUS
DOCUMENT NUMBER: 139:138735
TITLE: Sedative non-benzodiazepine formulations
INVENTOR(S): O'Toole, Edel; Fogarty, Siobhan
PATENT ASSIGNEE(S): Biovail Laboratories Inc., Barbados
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003059349	A1	20030724	WO 2003-IE1	20030109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1469848	A1	20041027	EP 2003-729537	20030109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2002-346613P P 20020110
WO 2003-IE1 W 20030109

AB The invention provides for an enhanced absorption pharmaceutical composition comprising a plurality of microparticles, each microparticle comprising at least one sedative non-benzodiazepine, at least one spheronisation aid, and at least one solubility enhancer. The microparticles of the invention are further incorporated into an oral fast-dispersing dosage form. For example, microparticles were prepared containing zolpidem tartrate 15%, Gelucire 50/13 35%, and distilled monoglyceride (Myvaplex) 50%. Microparticles obtained were then coated for taste masking with a coating solution containing a 60:30:10 ratio of Eudragit NE30D, talc, and Methocel. The coated microparticles were used for preparation of tablets.

IT Dissolution

Drug bioavailability
Hypnotics and Sedatives
Solubilizers
(preparation of microparticles for enhanced oral bioavailability of non-benzodiazepine sedatives)

IT 60-87-7, Promethazine 113-18-8, Ethchlorvynol 302-17-0, Chloral hydrate 533-45-9, Clomethiazole 2218-68-0, Chloral betaine 19794-93-5, Trazodone 43200-80-2, Zopiclone 82626-48-0, Zolpidem 83366-66-9, Nefazodone 85650-52-8, Mirtazapine 99294-93-6, Zolpidem tartrate 138729-47-2, Esopiclone 151319-34-5, Zaleplon 162883-07-0, CCD 3693 **196597-26-9, TAK 375** 325715-02-4, Indiplon 565462-01-3, Co 32693 565462-02-4, IP 100-9 565462-03-5, PPRT 211
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of microparticles for enhanced oral bioavailability of non-benzodiazepine sedatives)

IT **196597-26-9, TAK 375**
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of microparticles for enhanced oral bioavailability of non-benzodiazepine sedatives)

RN 196597-26-9 HCAPLUS
CN Propanamide, N-[2-[(8S)-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:167841 HCAPLUS
DOCUMENT NUMBER: 134:212749
TITLE: Matrix adhering to nasal mucosa
INVENTOR(S): Akiyama, Yoko; Nagahara, Naoki; Bando, Hiroto
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001015735	A1	20010308	WO 2000-JP5739	20000825

W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ,

BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

JP 2001131057	A2	20010515	JP 2000-255493	20000825
EP 1206943	A1	20020522	EP 2000-991043	20000825
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
US 6663883	B1	20031216	US 2002-69072	20020221
PRIORITY APPLN. INFO.:			JP 1999-240162	A 19990826
			WO 2000-JP5739	W 20000825

OTHER SOURCE(S): MARPAT 134:212749

AB Disclosed is a matrix adhering to the nasal mucosa which allows improved transfer into the brain of a drug exerting its effect in the brain and is capable of continuously supplying the drug into the brain. This matrix contains a polyglycerol fatty acid ester, the drug exerting its effect in the brain, and a sticky substance. Polyglycerol docosanoate (HB 310) and hydrogenated castor oil were heated. To the above mixture, cephalexin and Hiviswako 104 were added and the resulting mixture was made into granules.

IT Antidepressants
Brain
Drug bioavailability
Hypnotics and Sedatives
Tranquilizers
(matrix adhering to nasal mucosa for improved drug transfer to brain)

IT 9004-64-2, Hydroxypropyl cellulose 15686-71-2, Cephalexin 25618-55-7D, Polyglycerin, fatty acid esters 64366-79-6, HB 310 89286-85-1, Hiviswako 104 162874-49-9, Kadoran **196597-26-9**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(matrix adhering to nasal mucosa for improved drug transfer to brain)

IT **196597-26-9**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(matrix adhering to nasal mucosa for improved drug transfer to brain)

RN 196597-26-9 HCAPLUS
CN Propanamide, N-[2-[(8S)-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:	1995:943453 HCAPLUS
DOCUMENT NUMBER:	123:340087
TITLE:	Preparation of indolines which are melatonin receptor agonists and antagonists
INVENTOR(S):	North, Peter Charles; Carter, Malcolm Clive
PATENT ASSIGNEE(S):	Glaxo Group Ltd., UK
SOURCE:	PCT Int. Appl., 42 pp. CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9517405	A1	19950629	WO 1994-EP4220	19941220
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9410056	A	19951018	ZA 1994-10056	19941219
CA 2179402	AA	19950629	CA 1994-2179402	19941220
AU 9512743	A1	19950710	AU 1995-12743	19941220
AU 684877	B2	19980108		
EP 736028	A1	19961009	EP 1995-903817	19941220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
IL 112097	A1	19980615	IL 1994-112097	19941221
US 5633276	A	19970527	US 1996-652460	19960614
PRIORITY APPLN. INFO.:			GB 1993-26192	19931222
			WO 1994-EP4220	19941220

OTHER SOURCE(S): MARPAT 123:340087
GI



I

AB The title compds. [I; R1 = H, halogen, C1-6 alkyl; R2 = CR3R4(CH2)pNR5COR6; R3-R5 = H, C1-6 alkyl; R6 = C1-6 alkyl, C3-7 cycloalkyl; p = 1-4; n = 2-4], useful as melatonin receptor agonists and antagonists in the treatment of conditions associated with a disturbed functioning of the melatonin system [i.e., jet lag (no data), osteoporosis (no data), CNS disorders (no data), etc. (no data)], are prepared and I-containing formulations presented. Thus, 2-(5-chloro-2,3,7,8-tetrahydro-1H-furo[2,3-g]indol-1-yl)ethylamine was amidated with Ac2O, producing N-[2-(5-chloro-2,3,7,8-tetrahydro-1H-furo[2,3-g]indol-1-yl)ethyl]acetamide, m.p. 147-149°, which demonstrated a IC50 against the binding of melatonin to rabbit retina of 0.004 nM.

IT **Nervous system agents**
(indolines which are melatonin receptor agonists and antagonists)

IT **170728-91-3P 170728-92-4P 170729-12-1P 170729-13-2P 170729-14-3P 170729-15-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolines which are melatonin receptor agonists and antagonists)

IT **170728-91-3P 170728-92-4P 170729-12-1P**

170729-13-2P 170729-14-3P 170729-15-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolines which are melatonin receptor agonists and antagonists)

RN 170728-91-3 HCAPLUS
CN Acetamide, N-[2-(2,3,8,9-tetrahydropyrano[2,3-g]indol-1(7H)-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 170728-92-4 HCAPLUS
CN Acetamide, N-[2-(2,3,8,9-tetrahydropyrano[2,3-g]indol-1(7H)-yl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 170729-12-1 HCAPLUS
CN Acetamide, N-[2-(2,3,7,8-tetrahydro-1H-furo[2,3-g]indol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 170729-13-2 HCAPLUS
CN Acetamide, N-[2-(2,3,7,8-tetrahydro-1H-furo[2,3-g]indol-1-yl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 170729-14-3 HCAPLUS
CN Cyclopropanecarboxamide, N-[2-(2,3,7,8-tetrahydro-1H-furo[2,3-g]indol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 170729-15-4 HCAPLUS
CN Acetamide, N-[2-(5-chloro-2,3,7,8-tetrahydro-1H-furo[2,3-g]indol-1-yl)ethyl]- (9CI) (CA INDEX NAME)



=>